Most approaches to hypoxia-responsive drug delivery have utilized nitroaromatic or quinone derivatives due to up-regulation of bioreductive enzymes, including nitroreductase, azoreductase, and quinone reductase in many human cancers [7,12,13]. The gene discussed is NQO1; the disease is cancer.